Literature DB >> 9414177

Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.

C A Zahnow1, P Younes, R Laucirica, J M Rosen.   

Abstract

BACKGROUND: When cells fail to maintain a balance between proliferation, terminal differentiation, and programmed cell death, cancer often results. The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors regulates many genes involved in the processes of proliferation and terminal differentiation. The messenger RNA for C/EBPbeta is translated into two major isoforms, LAP (liver-enriched activating protein) and LIP (liver-enriched inhibitory protein). LIP levels appear to be elevated in mouse mammary tumors but not in hyperplastic mammary tissues. We tested whether LIP expression is elevated in human breast cancer and whether elevated expression is associated with biologic predictors of the aggressiveness of the disease.
METHODS: Homogenates of infiltrating ductal carcinoma specimens from 39 women were analyzed for C/EBPbeta protein content by western blot analysis, and the ratio of LAP to LIP in specimens containing high levels of LIP (i.e., levels approximately 15 times higher than those in tumor specimens that express little or no LIP) was also determined. Nonparametric statistical analyses were performed.
RESULTS: LIP was present at high levels in nine of 39 specimens of infiltrating ductal carcinoma. Eight of the nine specimens of infiltrating ductal carcinoma that contained high levels of LIP were negative for estrogen receptor and progesterone receptor (ER-/PR-); all nine tumors were aneuploid and poorly differentiated, and eight of nine were highly proliferative. Of the tumors that contained LIP at low or nondetectable levels, six of 30 were ER-/PR-, 17 of 29 were aneuploid, eight of 27 were highly proliferative, and 11 of 30 were poorly differentiated. IMPLICATION: LIP expression should be evaluated further as a prognostic marker for patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414177     DOI: 10.1093/jnci/89.24.1887

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  49 in total

Review 1.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 2.  Exploring the molecular etiology of dominant-negative mutations.

Authors:  Reiner A Veitia
Journal:  Plant Cell       Date:  2007-12-14       Impact factor: 11.277

Review 3.  C/EBPß Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think!

Authors:  Aaron J Spike; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-20       Impact factor: 2.673

4.  MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Akriti Kharbanda; Donald Kufe
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

5.  Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells.

Authors:  Brenda R Baldwin; Nikolai A Timchenko; Cynthia A Zahnow
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 6.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  EGFR and C/EBP-β oncogenic signaling is bidirectional in human glioma and varies with the C/EBP-β isoform.

Authors:  Ligia Selagea; Alok Mishra; Monika Anand; James Ross; Carol Tucker-Burden; Jun Kong; Daniel J Brat
Journal:  FASEB J       Date:  2016-08-29       Impact factor: 5.191

Review 8.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

9.  CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland.

Authors:  Heather L LaMarca; Adriana P Visbal; Chad J Creighton; Hao Liu; Yiqun Zhang; Fariba Behbod; Jeffrey M Rosen
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

10.  Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.

Authors:  Jihong Ma; Marie C DeFrances; Chunbin Zou; Carla Johnson; Robert Ferrell; Reza Zarnegar
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.